An investigational anti-HER2 (ERBB2) antibody–drug conjugate administered intravenously every 21 days (1–8 mg/kg). The monoclonal antibody targets HER2 on tumor cells, is internalized, and releases a cytotoxic payload to induce tumor cell death; payload not disclosed.